---
type: "Nootropic"
title: "taurine"
description: "Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking."
resource: "https://nootropikler.com/nootropics/taurine"
tags: ["Amino Sulfonic Acid", "Cognition research"]
timestamp: 2026-11-11T00:00:00Z
category: "Mood"
source: "Natural"
latin: "2-Aminoethanesulfonic acid"
language: "en"
---

# taurine

*2-Aminoethanesulfonic acid*

Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Half life | ~1 Hour |
| Dose used in research | No established dose for cognitive use |
| Safety | See detailed safety warnings |

> Correction 2026-11-11: Animal lifespan, human biomarker observations and the blood-pressure trial were separated. The one-hour value was linked to a small human plasma study. The generic evidence grade, sleep/anxiety mechanism table and mandatory-supplement inference were removed.

## What is Taurine?

Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking.

Taurine is an amino sulfonic acid with a sulfonic acid group instead of a carboxylic acid group. It is not a standard protein-building amino acid.

## Longevity Connection

Singh 2023 reported improved lifespan in mice and worms and health measures in monkeys with taurine; lifespan extension was not demonstrated in monkeys or humans. Human associations were not a supplementation trial.

Animal mechanisms do not establish human anti-aging treatment, sleep/anxiety benefit or personal dosing. Healthspan and total lifespan are different outcomes.

Fernandez 2025: Circulating taurine increased or remained unchanged with age in three human cohorts and observations in monkeys and mice. Health associations varied; declining taurine was not a universal aging marker.

The human component is observational, with longitudinal and cross-sectional measures. It does not test supplementation efficacy or inefficacy; a single plasma value diagnoses neither aging nor supplement need.

## Clinical Trials

Sun 2016: 120 people with prehypertension were randomized to 1.6 g/day taurine or placebo for 12 weeks. Mean clinic systolic reduction from baseline was 7.2/2.6 mmHg for taurine/placebo; this is not an extra 7.2 mmHg over placebo.

A patient-group blood-pressure result is neither cognitive benefit nor a direct interaction trial with antihypertensive drugs. Possible additive hypotension requires clinical assessment; do not independently change treatment.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Ghandforoush-Sattari 2010: In eight healthy fasted men given 4 g oral taurine, plasma elimination half-life was 1.0 ±0.3 hours and Tmax 1.5 ±0.6 hours. This is a small human pharmacokinetic study.

About one hour is the educational model's source value; 4 g is not personal-use advice. Tmax is not clinical onset; endogenous taurine, brain levels and whole-body stores are not measured by this curve.

## Safety and Side Effects

EFSA's 2009 opinion assessed taurine and glucuronolactone as individual ingredients at modeled energy-drink exposure. It did not assess whole energy drinks, every mixture or cognitive efficacy.

A historical exposure assessment is not approval of 6 g/day supplementation for everyone or a personal safe upper limit. Caffeine, alcohol, pregnancy and long-term high-dose safety cannot be inferred from it.

A human taurine trial found lower blood pressure; possible additional lowering with antihypertensives needs assessment. This does not mean the combination was directly tested. EFSA's energy-drink ingredient assessment is not general supplement safety; missing records do not establish safety.


## Frequently Asked Questions

### What does taurine do?

Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking.

### Does the EFSA opinion establish safety of all energy drinks?

EFSA's 2009 opinion assessed taurine and glucuronolactone as individual ingredients at modeled energy-drink exposure. It did not assess whole energy drinks, every mixture or cognitive efficacy. A historical exposure assessment is not approval of 6 g/day supplementation for everyone or a personal safe upper limit. Caffeine, alcohol, pregnancy and long-term high-dose safety cannot be inferred from it.

### Is Taurine good for sleep?

Taurine is a natural amino sulfonic acid. Neurotransmission mechanisms are investigated; adequate clinical evidence for treating insomnia or anxiety or improving cognition in humans is lacking.

### Does plasma taurine establish a need for supplementation?

The human component is observational, with longitudinal and cross-sectional measures. It does not test supplementation efficacy or inefficacy; a single plasma value diagnoses neither aging nor supplement need.

## Sources

- Singh P, et al. (2023). Taurine deficiency as a driver of aging. *Science*, 380(6649), eabn9257. [PubMed · PMID 37289866](https://pubmed.ncbi.nlm.nih.gov/37289866/)
- Jakaria M, et al. (2019). Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms. *Redox Biology*, 24, 101223. [PubMed · PMID 31141786](https://pubmed.ncbi.nlm.nih.gov/31141786/)
- Bkaily G, et al. (2020). Taurine and cardiac disease: State of the art and perspectives. *Canadian Journal of Physiology and Pharmacology*. [PubMed · PMID 31560859](https://pubmed.ncbi.nlm.nih.gov/31560859/)
- El Idrissi A, Trenkner E. (2004). Taurine as a modulator of excitatory and inhibitory neurotransmission. *Neurochemical Research*, 29(1), 189–197. [PubMed · PMID 14992278](https://pubmed.ncbi.nlm.nih.gov/14992278/)
- Fernandez ME, et al. (2025). Is taurine an aging biomarker?. *Science*, 388(6751), eadl2116. https://doi.org/10.1126/science.adl2116 [PubMed · PMID 40472098](https://pubmed.ncbi.nlm.nih.gov/40472098/)
- European Food Safety Authority (EFSA). (2009). The use of taurine and D-glucurono-gamma-lactone as constituents of the so-called “energy” drinks. *EFSA Journal*, 7(2), 935. https://doi.org/10.2903/j.efsa.2009.935 [Publisher record · DOI · European Food Safety Authority](https://doi.org/10.2903/j.efsa.2009.935)
- Ghandforoush-Sattari M, et al. (2010). Pharmacokinetics of oral taurine in healthy volunteers. *Journal of amino acids*, 2010, 346237. https://doi.org/10.4061/2010/346237 [PubMed · PMID 22331997](https://pubmed.ncbi.nlm.nih.gov/22331997/)
- Sun Q, et al. (2016). Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. *Hypertension*, 67(3), 541-9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06624 [PubMed · PMID 26781281](https://pubmed.ncbi.nlm.nih.gov/26781281/)

## Related nootropics

- [L-Theanine](/okf/nootropics/l-theanine.md)
- [Apigenin](/okf/nootropics/apigenin.md)
- [Mg L-Threonate](/okf/nootropics/magnesium-l-threonate.md)
